| News Updates |
 |
CANN Celebrates Biden Administration Protecting Medicare Part D
Community Access national Network | March 2021
|
|
Certain HIV Meds May Trigger Weight Gain
WebMD | March 16, 2021
|
|
Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV
Business Wire | March 15, 2021
|
|
Another HIV Tivicay Birth Outcome: Better Infant Survival
Medscape | MARCH 15, 2021
|
|
PAF’s Co-Pay Relief Expands Assistance to Cover Insurance Premiums (including HIV/AIDS Fund).
ADAP | MARCH 11, 2021
|
|
CROI: GILEAD'S INVESTIGATIONAL LENACAPAVIR DEMONSTRATES SUSTAINED LONG-ACTING EFFICACY THROUGH WEEK 26 IN DATA PRESENTED AT CROI
NATAP | CROI 2021 March 6-10 |
|
CROI: PHASE IIA PROOF-OF-CONCEPT TRIAL OF NEXT-GENERATION MATURATION INHIBITOR GSK3640254
NATAP | CROI 2021 March 6-10 |
|
CROI: GSK3640254 IS A NOVEL MATURATION INHIBITOR WITH AN OPTIMIZED VIROLOGY PROFILE
NATAP | CROI 2021 March 6-10 |
|
CROI: NNRTI MK-8507 SELECTS V106 MUTATIONS, ACTIVE AGAINST COMMON NNRTI MUTATIONS
NATAP | CROI 2021 March 6-10 |
|
CROI: CLINICAL EVALUATION OF DRUG INTERACTIONS WITH ORAL LENACAPAVIR AND PROBE DRUGS
NATAP | CROI 2021 March 6-10 |
|
CROI: ACTIVITY AND RESISTANCE CHARACTERIZATION OF THE HIV CAPSID INHIBITOR LENACAPAVIR
NATAP | CROI 2021 March 6-10 |
|
CROI: POTENT ANTIVIRAL ACTIVITY OF LENACAPAVIR IN PHASE 2/3 IN HEAVILY ART-EXPERIENCED PWH
NATAP | CROI 2021 March 6-10 |
|
Revisions to TRIUMEQ and DOVATO labeling
FDA | March 2, 2021
|
|
Op-ed: Six Protected Classes and Protecting People with HIV
plus | February 26, 2021
|
|
ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Expanded Use of Cabenuva (cabotegravir, rilpivirine) as an HIV Treatment for Use Every 2-Months
ViiV Healthcare | February 24, 2021
|
|
Ask the Doctors: New HIV treatment administered monthly
Lompoc Record | February 18, 2021
|
|
FDA Approves Cabenuva and Vocabria for the Treatment of HIV-1 Infection
ViiV Healthcare | January 21, 2021
|
|
MAT Provides Patients with More Transparency Around Medicine Costs
ADAP Advocacy Association | January 21, 2021
Emma Berry, Advocacy & Strategic Alliances, Pharmaceutical Research and Manufacturers of America (PhRMA).
|
|
Tivicay approved in Europe in new dispersible tablet for children with HIV
pharmaphorum | January 14, 2021
|
|
Valganciclovir and Ganciclovir Effective for HIV-Associated CMVR in Low- and Middle-Income Countries
Infectious Disease Advisor | January 11, 2021
|
|
Many health plans now must cover full cost of expensive HIV prevention drugs
Duluth News Tribune | January 10, 2021
|
|
Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States
HIV.gov | December 29, 2021
|
|
ViiV Healthcare announces the Marketing Authorisation of the first complete long-acting injectable HIV treatment in Europe
ViiV Healthcare | December 21, 2020
|
|
Update to CDC's Treatment for Gonococcal Infections, 2020
CDC | December 18, 2020
|
|
Fact Sheet for Recipients and Caregivers: Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19) in Individuals 16 Years of Age and Older
FDA | December 2020
|
|
Long-Lasting Anti-AIDS Meds Eliminate 'Psychic Toll' Of Daily Pill
NPR | November 19, 2020
|
|
Salivary flow, amylase, and total protein in hospitalized patients with HIV infection / AIDS complications
Afr Health Sci. 2020 Jun;20(2):597-604. doi: 10.4314/ahs.v20i2.7.
|
|
Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1
Merck | November 16, 2020
|
|
Changes to SELZENTRY (maraviroc) labeling to include safety and PK data in pediatric patients weighing at least 2 kg
FDA | November 2, 2020
|
|
ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV
PipelineReview.com | October 17, 2020
|
|
Janssen Receives Positive CHMP Opinion for Long-Acting Regimen for the Treatment of HIV
PipelineReview.com | October 16, 2020
|
|
Experimental Antiretroviral Has Potential for Once-Weekly HIV Treatment
POZ | October 16, 2020
|
|
Gilead's Biktarvy sustains viral suppression and tolerability in Asian HIV patients
BSA bureau | October 15, 2020
|
|
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society–USA Panel
Journal of the American Medical Association | October 14, 2020
|
|
Switching HIV Meds to Long-Acting Cabenuva May Not Require Oral Lead-In
POZ | October 9, 2020
|
|
Dentists, do you know which drugs do not mix with remdesivir?
Dr Bicuspid | October 8, 2020
|
|
Treatment With Islatravir and Doravirine Maintained Viral Suppression and No Viral Resistance was Identified
PipelineReview.com | October 8, 2020
|
|
HIV Regimen of Islatravir and Pifeltro Doesn’t Appear to Affect Kidney Function
POZ | October 7, 2020
|
|
Injectable HIV therapy should save money if adherence is better than to oral therapies
aidsmap | October 7, 2020
|
|
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial
PubMed | 2020 Oct;7(10):e666-e676. doi: 10.1016/S2352-3018(20)30241-1 |
|
Gilead's Truvada faces Teva generics assault amid Descovy switching campaign
FiercePharma | October 2, 2020
|
| |
|
